The results presented that MIR4435-2HG was significantly positively correlated to CD274 (r = 0.12; p = 0.014), CTLA4 (r = 0.27; p = 1.4e − 08), HAVCR2 (r = 0.19; p = 6.4e − 05), IDO1 (r = 0.13; p = 0.0075), PDCD1 (r = 0.13; p = 0.0086), and PDCD1LG2 (r = 0.16; p = 0.001; Figures 7E–J), suggesting MIR4435-2HG may be a novel and potential target in ICB treatment in HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.